Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines buys royalty rate reduction from Eli Lilly
Specifically, the top tier royalty rate will be reduced three percentage points and the middle tier royalty rate will be reduced one half percentage point. The bottom tier
Specifically, the top tier royalty rate will be reduced three percentage points and the middle tier royalty rate will be reduced one half percentage point. The bottom tier
Working collaboratively with the vice president of international sales and the management team, Ms Gaston will lead the development and implementation of a strategic sales plan focused exclusively
The company will be called Daiichi Sankyo Ireland and be headquartered in Dublin. In addition to the osteoporosis medication Evista, Daiichi Sankyo Ireland will market the anti-hypertensive product
The new patent’s allowed claims include methods of treating a broad spectrum of viral infections, including HIV, influenza, hepatitis C virus and cytomegalovirus, using one or more anti-phospholipid
The CE Mark allows Kinetic Concepts (KCI) to begin marketing Strattice in all 27 member states. Strattice has previously received 510(k) clearance from the FDA and has been
The Acord trial will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Approximately 30 sites are expected to participate. CardioVascular BioTherapeutics’s
The patents cover a technology that allows for the rapid characterization of the potency of bone marrow-derived cells in the treatment of cardiovascular diseases. The potency of stem
The two-armed, randomized clinical trial has enrolled 200 patients at sites in the Philippines, Korea, India, Malaysia, Thailand, Hong Kong, Singapore, Serbia, Poland, Croatia, and Italy. The primary
Under the terms of the agreement, Watson will acquire the portfolio of products for an upfront payment of $36 million and will make additional payments to Teva when
Abraxis has developed an extensive clinical program that the company believes will form the basis for new indications for Abraxane as well as other product candidates for which